Keywords
Last Name
Institution

Thomas E. Keane

TitleChair, Department of Urology
InstitutionMedical University of South Carolina
DepartmentUrology
AddressP.O. Box MSC 620
644
96 Jonathan Lucas St.
Phone843-792-0534
Fax843-792-4870
vCardDownload vCard

    Collapse Overview 
    Collapse keywords
    Bladder, Cancer, Cancer/Genitourinary, Kidney, Men-s Health, Drug Studies, Women-s Health

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol. 2019 04; 201(4):682-692. PMID: 30077557.
      View in: PubMed
    2. Crawford ED, Tombal B, Keane T, Boccardo F, Miller K, Shore N, Moul JW, Damber JE, Collette L, Persson BE. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2018 Oct - Dec; 52(5-6):349-357. PMID: 30624128.
      View in: PubMed
    3. Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A, Tward J, Scardino P, Brawer M, Stone S, Cuzick J. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urol Oncol. 2018 06; 36(6):310.e7-310.e13. PMID: 29655620.
      View in: PubMed
    4. Greiman AK, Keane TE. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. Curr Urol Rep. 2017 Jun; 18(6):41. PMID: 28417429.
      View in: PubMed
    5. Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, Eckel RH, Keane TE, Shore ND, Dahdal DN, Beveridge TJR, Marshall DC. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017 05; 35(5):183-191. PMID: 28325650.
      View in: PubMed
    6. Crawford ED, Petrylak DP, Shore N, Saad F, Slovin SF, Vogelzang NJ, Keane TE, Koo PJ, Gomella LG, O'Sullivan JM, Tombal B, Concepcion RS, Sieber P, Stone NN, Finkelstein SE, Yu EY. The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology. 2017 Jun; 104:150-159. PMID: 28302580.
      View in: PubMed
    7. Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, Miller K, Kim CS, Kimura G, Armstrong AJ, Sternberg CN, Loriot Y, de Bono J, Noonberg SB, Mansbach H, Bhattacharya S, Perabo F, Beer TM, Tombal B. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 10; 70(4):675-683. PMID: 27006332.
      View in: PubMed
    8. Greiman A, Shah J, Bhavsar R, Armeson K, Caulder S, Jones R, Keane TE, Clarke HS, Savage SJ. Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients With Elevated Serum Prostate-specific Antigen Is Not Clinically Beneficial: A Randomized Controlled Clinical Trial. Urology. 2016 Apr; 90:32-7. PMID: 26802800.
      View in: PubMed
    9. Crawford ED, Albala DM, Wysocki JS, Lepor H, Ross AE, Finkelstein SE, Keane T, Freedland S, Harris R, Shore ND, Ryan CJ. Prostate Cancer Academy 2016: Presentation summaries. Rev Urol. 2016; 18(4):205-213. PMID: 28127262.
      View in: PubMed
    10. Shore ND, Karsh L, Gomella LG, Keane TE, Concepcion RS, Crawford ED. Avoiding obsolescence in advanced prostate cancer management: a guide for urologists. BJU Int. 2015 Feb; 115(2):188-97. PMID: 25756134.
      View in: PubMed
    11. Yu EY, Getzenberg RH, Coss CC, Gittelman MM, Keane T, Tutrone R, Belkoff L, Given R, Bass J, Chu F, Gambla M, Gaylis F, Bailen J, Hancock ML, Smith J, Dalton JT, Steiner MS. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb; 67(2):334-41. PMID: 24968970.
      View in: PubMed
    12. Chaudhary UB, Verma N, Keane T, Gudena V. A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer. Am J Clin Oncol. 2014 Apr; 37(2):188-93. PMID: 23241501.
      View in: PubMed
    13. Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014 Mar; 83(3):664-9. PMID: 24411213.
      View in: PubMed
    14. Marshall DT, Ramey S, Golshayan AR, Keane TE, Kraft AS, Chaudhary U. Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):80-6. PMID: 24378335.
      View in: PubMed
    15. Ramsey SD, Zeliadt SB, Blough DK, Moinpour CM, Hall IJ, Smith JL, Ekwueme DU, Fedorenko CR, Fairweather ME, Koepl LM, Thompson IM, Keane TE, Penson DF. Impact of prostate cancer on sexual relationships: a longitudinal perspective on intimate partners' experiences. J Sex Med. 2013 Dec; 10(12):3135-43. PMID: 24118980.
      View in: PubMed
    16. Cheng JC, Bai A, Beckham TH, Marrison ST, Yount CL, Young K, Lu P, Bartlett AM, Wu BX, Keane BJ, Armeson KE, Marshall DT, Keane TE, Smith MT, Jones EE, Drake RR, Bielawska A, Norris JS, Liu X. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. 2013 Oct; 123(10):4344-58. PMID: 24091326.
      View in: PubMed
    17. Li C, Zeliadt SB, Hall IJ, Smith JL, Ekwueme DU, Moinpour CM, Penson DF, Thompson IM, Keane TE, Ramsey SD. Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective. Support Care Cancer. 2013 Dec; 21(12):3461-9. PMID: 23955026.
      View in: PubMed
    18. Hardie AD, Rieter WJ, Bradshaw ML, Gordon LL, Young MA, Keane TE. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer. World J Urol. 2013 Dec; 31(6):1327-32. PMID: 23595605.
      View in: PubMed
    19. Prasad SM, Keane T, Bennett CL. Editorial comment. Urology. 2012 Sep; 80(3):563. PMID: 22789296.
      View in: PubMed
    20. Li C, Zeliadt SB, Hall IJ, Smith JL, Ekwueme DU, Moinpour CM, Penson DF, Thompson IM, Keane TE, Ramsey SD. Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. Value Health. 2012 Jul-Aug; 15(5):716-23. PMID: 22867781.
      View in: PubMed
    21. Schröder F, Crawford ED, Axcrona K, Payne H, Keane TE. Androgen deprivation therapy: past, present and future. BJU Int. 2012 Jun; 109 Suppl 6:1-12. PMID: 22672120.
      View in: PubMed
    22. Prasad SM, Keane TE, Bennett CL. Editorial comment. Urology. 2012 Jul; 80(1):168. PMID: 22608794.
      View in: PubMed
    23. Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL, Ambrose LH, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012 Jul; 97(7):2315-24. PMID: 22508710.
      View in: PubMed
    24. Deem S, Keane T, Bhavsar R, El-Zawahary A, Savage S. Contemporary diagnosis and management of squamous cell carcinoma (SCC) of the penis. BJU Int. 2011 Nov; 108(9):1378-92. PMID: 22023060.
      View in: PubMed
    25. Rieter WJ, Keane TE, Ahlman MA, Ellis CT, Spicer KM, Gordon LL. Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer. Clin Nucl Med. 2011 Oct; 36(10):872-8. PMID: 21892036.
      View in: PubMed
    26. Dasgupta S, Shao C, Keane TE, Duberow DP, Mathies RA, Fisher PB, Kiemeney LA, Sidransky D. Detection of mitochondrial deoxyribonucleic acid alterations in urine from urothelial cell carcinoma patients. Int J Cancer. 2012 Jul 01; 131(1):158-64. PMID: 21826645.
      View in: PubMed
    27. Rim SH, Hall IJ, Fairweather ME, Fedorenko CR, Ekwueme DU, Smith JL, Thompson IM, Keane TE, Penson DF, Moinpour CM, Zeliadt SB, Ramsey SD. Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population. Int J Gen Med. 2011; 4:481-6. PMID: 21760749.
      View in: PubMed
    28. McIntyre M, Weiss A, Wahlquist A, Keane T, Clarke H, Savage S. Penile cancer: an analysis of socioeconomic factors at a southeastern tertiary referral center. Can J Urol. 2011 Feb; 18(1):5524-8. PMID: 21333043.
      View in: PubMed
    29. Zeliadt SB, Penson DF, Moinpour CM, Blough DK, Fedorenko CR, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD. Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int. 2011 Sep; 108(6):851-6; discussion 856-7. PMID: 21244609.
      View in: PubMed
    30. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Colombel M, Klotz L, Skinner E, Keane T, Marreaud S, Collette S, Sylvester R. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011 Apr; 59(4):543-52. PMID: 21186077.
      View in: PubMed
    31. Turner LS, Cheng JC, Beckham TH, Keane TE, Norris JS, Liu X. Autophagy is increased in prostate cancer cells overexpressing acid ceramidase and enhances resistance to C6 ceramide. Prostate Cancer Prostatic Dis. 2011 Mar; 14(1):30-7. PMID: 21116286.
      View in: PubMed
    32. El-Zawahry AM, Clarke HS, Eskridge MR, Rieter W, Onicescu G, Garrett-Mayer E, Gordon LL, Keane TE. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate. Urology. 2010 Nov; 76(5):1162-7. PMID: 20434196.
      View in: PubMed
    33. Ramsey SD, Zeliadt SB, Fedorenko CR, Blough DK, Moinpour CM, Hall IJ, Smith JL, Ekwueme DU, Fairweather ME, Thompson IM, Keane TE, Penson DF. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol. 2011 Feb; 29(1):3-9. PMID: 20959991.
      View in: PubMed
    34. Lawrence C, Siddiqi MF, Hamilton JN, Keane TE, Romagnuolo J, Hawes RH, Cotton PB. Chronic calcific pancreatitis: combination ERCP and extracorporeal shock wave lithotripsy for pancreatic duct stones. South Med J. 2010 Jun; 103(6):505-8. PMID: 20710131.
      View in: PubMed
    35. Zeliadt SB, Moinpour CM, Blough DK, Penson DF, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD. Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care. 2010 May 01; 16(5):e121-30. PMID: 20455638.
      View in: PubMed
    36. Liu X, Cheng JC, Turner LS, Elojeimy S, Beckham TH, Bielawska A, Keane TE, Hannun YA, Norris JS. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009 Dec; 13(12):1449-58. PMID: 19874262.
      View in: PubMed
    37. Picard JC, Golshayan AR, Marshall DT, Opfermann KJ, Keane TE. The multi-disciplinary management of high-risk prostate cancer. Urol Oncol. 2012 Jan-Feb; 30(1):3-15. PMID: 19945310.
      View in: PubMed
    38. Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, Bai A, Gault CR, McPherson AS, Garcia N, Beckham TH, Saad A, Bielawska A, Bielawski J, Hannun YA, Keane TE, Taha MI, Hammouda HM, Norris JS, Liu X. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009 Mar; 17(3):430-8. PMID: 19107118.
      View in: PubMed
    39. Parra G, Bradnam K, Ning Z, Keane T, Korf I. Assessing the gene space in draft genomes. Nucleic Acids Res. 2009 Jan; 37(1):289-97. PMID: 19042974.
      View in: PubMed
    40. Bong GW, Ritenour CW, Osunkoya AO, Smith MT, Keane TE. Evaluation of modern pathological criteria for positive margins in radical prostatectomy specimens and their use for predicting biochemical recurrence. BJU Int. 2009 Feb; 103(3):327-31. PMID: 19007381.
      View in: PubMed
    41. Varela JC, Atkinson C, Woolson R, Keane TE, Tomlinson S. Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int J Cancer. 2008 Sep 15; 123(6):1357-63. PMID: 18561323.
      View in: PubMed
    42. Yoost TR, Bong GW, Keane TE. Perineal prostatectomy in the age of minimally invasive surgery. J Ark Med Soc. 2008 Sep; 105(3):67-8. PMID: 18828477.
      View in: PubMed
    43. Bong GW, Clarke HS, Hancock WC, Keane TE. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology. 2008 Jun; 71(6):1177-80. PMID: 18279929.
      View in: PubMed
    44. Liu X, Elojeimy S, Turner LS, Mahdy AE, Zeidan YH, Bielawska A, Bielawski J, Dong JY, El-Zawahry AM, Guo GW, Hannun YA, Holman DH, Rubinchik S, Szulc Z, Keane TE, Tavassoli M, Norris JS. Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 01; 13:2293-8. PMID: 17981711.
      View in: PubMed
    45. Grossman HB, O'Donnell MA, Cookson MS, Greenberg RE, Keane TE. Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol. 2008; 10(4):281-9. PMID: 19145271.
      View in: PubMed
    46. Ramirez ML, Keane TE, Evans CP. Managing prostate cancer: the role of hormone therapy. Can J Urol. 2007 Dec; 14 Suppl 1:10-8. PMID: 18163939.
      View in: PubMed
    47. Clarke HS, Eskridge MR, El-Zawahry AM, Keane TE. Salvage cryosurgical ablation of the prostate for local recurrence after radiation therapy: improved outcomes utilizing a capromab pendetide scan and biopsy algorithm. Can J Urol. 2007 Dec; 14 Suppl 1:24-7. PMID: 18163941.
      View in: PubMed
    48. Bong GW, Keane TE. Salvage options for biochemical recurrence after primary therapy for prostate cancer. Can J Urol. 2007 Dec; 14 Suppl 1:2-9. PMID: 18163938.
      View in: PubMed
    49. Savage SJ, Wingo MS, Hooper HB, Smith MT, Keane TE. Pathologically confirmed port site metastasis after laparoscopic radical prostatectomy: case report and literature review. Urology. 2007 Dec; 70(6):1222.e9-11. PMID: 18158058.
      View in: PubMed
    50. Cummings B, Keane T, Pintilie M, Warde P, Waldron J, Payne D, Liu FF, Bissett R, McLean M, Gullane P, O'Sullivan B. Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol. 2007 Oct; 85(1):7-16. PMID: 17920715.
      View in: PubMed
    51. Bullard RS, Gibson W, Bose SK, Belgrave JK, Eaddy AC, Wright CJ, Hazen-Martin DJ, Lage JM, Keane TE, Ganz TA, Donald CD. Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol Immunol. 2008 Feb; 45(3):839-48. PMID: 17868871.
      View in: PubMed
    52. Fleshner N, Keane TE, Lawton CA, Mulders PF, Payne H, Taneja SS, Morris T. Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11(1):46-52. PMID: 17607304.
      View in: PubMed
    53. Guerrero MA, Cross CA, Lin PH, Keane TE, Lumsden AB. Inferior vena cava reconstruction using fresh inferior vena cava allograft following caval resection for leiomyosarcoma: midterm results. J Vasc Surg. 2007 Jul; 46(1):140-3. PMID: 17606132.
      View in: PubMed
    54. Saad AF, Meacham WD, Bai A, Anelli V, Elojeimy S, Mahdy AE, Turner LS, Cheng J, Bielawska A, Bielawski J, Keane TE, Obeid LM, Hannun YA, Norris JS, Liu X. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther. 2007 Sep; 6(9):1455-60. PMID: 17881906.
      View in: PubMed
    55. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Marechal JM, Klotz L, Skinner E, Keane T, Claessens I, Sylvester R. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2007 Jun; 51(6):1606-15. PMID: 17140723.
      View in: PubMed
    56. Liu X, Zeidan YH, Elojeimy S, Holman DH, El-Zawahry AM, Guo GW, Bielawska A, Bielawski J, Szulc Z, Rubinchik S, Dong JY, Keane TE, Tavassoli M, Hannun YA, Norris JS. Involvement of sphingolipids in apoptin-induced cell killing. Mol Ther. 2006 Nov; 14(5):627-36. PMID: 16926120.
      View in: PubMed
    57. Liu X, Elojeimy S, El-Zawahry AM, Holman DH, Bielawska A, Bielawski J, Rubinchik S, Guo GW, Dong JY, Keane T, Hannun YA, Tavassoli M, Norris JS. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006 Nov; 14(5):637-46. PMID: 16887394.
      View in: PubMed
    58. Drake BF, Keane TE, Mosley CM, Adams SA, Elder KT, Modayil MV, Ureda JR, Hebert JR. Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology. J S C Med Assoc. 2006 Aug; 102(7):241-9. PMID: 17319238.
      View in: PubMed
    59. Moussa O, Abol-Enein H, Bissada NK, Keane T, Ghoneim MA, Watson DK. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol. 2006 Jun; 175(6):2312-6. PMID: 16697865.
      View in: PubMed
    60. Keane TE, Rosner IL, Wingo MS, McLeod DG. The emergence of radioimmunoscintigraphy for prostate cancer. Rev Urol. 2006; 8 Suppl 1:S20-8. PMID: 17021623.
      View in: PubMed
    61. Laudadio J, Keane TE, Reeves HM, Savage SJ, Hoda RS, Lage JM, Wolff DJ. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 2005 Dec; 96(9):1280-5. PMID: 16287445.
      View in: PubMed
    62. Parker R, Reeves HM, Sudarshan S, Wolff D, Keane T. Abnormal fluorescence in situ hybridization analysis in collecting duct carcinoma. Urology. 2005 Nov; 66(5):1110. PMID: 16286148.
      View in: PubMed
    63. Horger DC, Wingo MS, Keane TE. Partial segmental thrombosis of corpus cavernosum: case report and review of world literature. Urology. 2005 Jul; 66(1):194. PMID: 15921728.
      View in: PubMed
    64. Klotz L, Payne H, Gillatt D, Keane T, Morris C, Akaza H. [Reevaluation of MAB therapy and progress of endocrine therapy]. Gan To Kagaku Ryoho. 2005 May; 32(5):705-28. PMID: 15934164.
      View in: PubMed
    65. Corica FA, Keane TE. Bladder cancer--resection/ablation. Surg Oncol Clin N Am. 2005 Apr; 14(2):321-52. PMID: 15817242.
      View in: PubMed
    66. Norris JS, Norris KL, Holman DH, El-Zawahry A, Keane TE, Dong JY, Tavassoli M. The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck. Future Oncol. 2005 Feb; 1(1):115-23. PMID: 16555981.
      View in: PubMed
    67. Baker SD, Horger DC, Keane TE. Community-acquired methicillin-resistant Staphylococcus aureus prostatic abscess. Urology. 2004 Oct; 64(4):808-10. PMID: 15491738.
      View in: PubMed
    68. Bissada NK, Keane T, Caczmarek AT, El-Zawahry A, Fahmy WE, Bissada MA, Yakout HH. Experience with coapted gastric tube outlet and composite gastrointestinal reservoir for continent cutaneous urinary diversion. J Urol. 2004 Jan; 171(1):229-31. PMID: 14665882.
      View in: PubMed
    69. Schinazi RF, Hurwitz SJ, Liberman I, Glazkova Y, Mourier NS, Olson J, Keane T. Tissue disposition of 5-o-carboranyluracil--a novel agent for the boron neutron capture therapy of prostate cancer. Nucleosides Nucleotides Nucleic Acids. 2004; 23(1-2):291-306. PMID: 15043155.
      View in: PubMed
    70. Chaudhary UB, Rashid M, Keane TE. PC-SPES withdrawal response. Acta Oncol. 2004; 43(8):772-3. PMID: 15764226.
      View in: PubMed
    71. Lin PH, Terramani TT, Bush RL, Keane TE, Moore RG, Lumsden AB. Concomitant intraoperative renal artery embolization and resection of complex renal carcinoma. J Vasc Surg. 2003 Sep; 38(3):446-50. PMID: 12947251.
      View in: PubMed
    72. El-Galley R, Keane TE, Sun C. Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft. Urol Oncol. 2003 Jan-Feb; 21(1):49-57. PMID: 12684128.
      View in: PubMed
    73. Chodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology. 2002 Aug; 60(2):201-8. PMID: 12137810.
      View in: PubMed
    74. El-Galley R, Rutland H, Talic R, Keane T, Clark H. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol. 2001 Sep; 166(3):927-31. PMID: 11490248.
      View in: PubMed
    75. Perez-Brayfield MR, Keane TE, Krishnan A, Lafontaine P, Feliciano DV, Clarke HS. Gunshot wounds to the ureter: a 40-year experience at Grady Memorial Hospital. J Urol. 2001 Jul; 166(1):119-21. PMID: 11435836.
      View in: PubMed
    76. La Fata V, Ramachandran A, Galt J, Keane TE, Halkar R. Diuretic renogram in a patient with a urinary diversion: avoiding a false-positive diagnosis of obstruction with an indwelling catheter. Clin Nucl Med. 2001 Jul; 26(7):631-2. PMID: 11416749.
      View in: PubMed
    77. Brierley J, Wong CS, Cummings B, Catton P, Ringash J, Catton C, McLean M, Keane T, Panzarella T. Squamous cell carcinoma of the oesophagus treated with radiation and 5-fluorouracil, with and without mitomycin C. Clin Oncol (R Coll Radiol). 2001; 13(3):157-63. PMID: 11527287.
      View in: PubMed
    78. Desai S, Lim SD, Jimenez RE, Chun T, Keane TE, McKenney JK, Zavala-Pompa A, Cohen C, Young RH, Amin MB. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol. 2000 Dec; 13(12):1315-23. PMID: 11144928.
      View in: PubMed
    79. Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000 Aug; 86(3):203-7. PMID: 10930915.
      View in: PubMed
    80. el-Galley RE, Keane TE. Embryology, anatomy, and surgical applications of the kidney and ureter. Surg Clin North Am. 2000 Feb; 80(1):381-401, xiv. PMID: 10685158.
      View in: PubMed
    81. Jimenez RE, Keane TE, Hardy HT, Amin MB. pT1 urothelial carcinoma of the bladder: criteria for diagnosis, pitfalls, and clinical implications. Adv Anat Pathol. 2000 Jan; 7(1):13-25. PMID: 10640198.
      View in: PubMed
    82. Fischer AH, Wallace VL, Keane TE, Clarke HS. Two cases of vasculitis of the urinary bladder: diagnostic and pathogenetic considerations. Arch Pathol Lab Med. 1998 Oct; 122(10):903-6. PMID: 9786351.
      View in: PubMed
    83. El-Galley RE, Keane TE, Petros JA, Sanders WH, Clarke HS, Cotsonis GA, Graham SD. Evaluation of staging lymphadenectomy in prostate cancer. Urology. 1998 Oct; 52(4):663-7. PMID: 9763090.
      View in: PubMed
    84. Keane TE, El-Galley RE, Sun C, Petros JA, Dillahey D, Gomaa A, Graham SD, McGuire WP. Camptothecin analogues/cisplatin: an effective treatment of advanced bladder cancer in a preclinical in vivo model system. J Urol. 1998 Jul; 160(1):252-6. PMID: 9628659.
      View in: PubMed
    85. Chow E, Payne D, Keane T, Panzarella T, Izard MA. Enhanced control by radiotherapy of cervical lymph node metastases arising from nasopharyngeal carcinoma compared with nodal metastases from other head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 1997 Aug 01; 39(1):149-54. PMID: 9300749.
      View in: PubMed
    86. el-Galley RE, Petros JA, Sanders WH, Keane TE, Galloway NT, Cooner WH, Graham SD. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology. 1995 Aug; 46(2):200-4. PMID: 7542822.
      View in: PubMed
    87. O'Sullivan B, Warde P, Keane T, Irish J, Cummings B, Payne D. Outcome following radiotherapy in verrucous carcinoma of the larynx. Int J Radiat Oncol Biol Phys. 1995 Jun 15; 32(3):611-7. PMID: 7790246.
      View in: PubMed
    88. Keane TE, Graham SD. Conservative renal surgery. Has it a role in renal cell carcinoma? Surg Oncol Clin N Am. 1995 Apr; 4(2):295-306. PMID: 7796288.
      View in: PubMed
    89. Graham SD, Napalkov P, Oladele A, Keane TE, Petros JA, Clarke HS, Kassabian VS, Dillehay DL. Intravesical suramin in the prevention of transitional cell carcinoma. Urology. 1995 Jan; 45(1):59-63. PMID: 7817482.
      View in: PubMed
    90. Keane TE, Petros JA, Velimirovich B, Yue KT, Graham SD. Methoxypsoralen phototherapy of transitional cell carcinoma. Urology. 1994 Dec; 44(6):842-6. PMID: 7985313.
      View in: PubMed
    91. Keane TE, Gingrich JR, Rosner G, Webb KS, Poulton SH, Walther PJ. Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model. Cancer Res. 1994 Jan 15; 54(2):475-81. PMID: 8275484.
      View in: PubMed
    92. Geoghegan JG, Keane TE, Rosenberg IL, Dellipiani AW, Peel AL. Gastric cancer: the case for a more selective policy in surgical management. J R Coll Surg Edinb. 1993 Aug; 38(4):208-12. PMID: 7693929.
      View in: PubMed
    93. Fernandez JA, Keane TE, Weems WS, Carson CC. Use of protective plastic sheath for prostatic biopsy. Urology. 1992 Jan; 39(1):88-9. PMID: 1728804.
      View in: PubMed
    94. Keane TE, Rosner GL, Gingrich JR, Poulton SH, Walther PJ. The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer. J Urol. 1991 Nov; 146(5):1418-24. PMID: 1942313.
      View in: PubMed
    95. Keane TE, Rosner G, Donaldson JT, Norwood DL, Poulton SH, Walther PJ. Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. J Urol. 1990 Oct; 144(4):1004-9. PMID: 2398547.
      View in: PubMed
    96. Donaldson JT, Tucker JA, Keane TE, Walther PJ, Webb KS. Characterization of a new model of human prostatic cancer: the multicellular tumor spheroid. Int J Cancer. 1990 Aug 15; 46(2):238-44. PMID: 2200753.
      View in: PubMed
    97. Donaldson JT, Keane TE, Poulton SH, Walther PJ. Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model. Urol Res. 1990; 18(4):245-50. PMID: 2219586.
      View in: PubMed
    98. Heaney JA, Allen MA, Keane T, Duffy MJ. Prostate-specific antigen. Superior serum marker for prostatic carcinoma. Ir J Med Sci. 1987 May; 156(5):138-41. PMID: 2440830.
      View in: PubMed
    Keane's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _